Radical Prostatectomy Combined with Prostate Specific Membrane Antigen-radioguided Lymph Node Dissection is Associated with Longer Treatment-free Survival for Patients with Primary Lymph Node-positive Prostate Cancer.
기술보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
46 patients who underwent RP with RGS, and 42 patients who underwent RP without RGS, with matching according to LNM distribution, number of LNMs on preoperative PSMA PET scans, and surgical margin status.
I · Intervention 중재 / 시술
RP without RGS, with matching according to LNM distribution, number of LNMs on preoperative PSMA PET scans, and surgical margin status
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
We found that this approach may lead to better cancer control after surgery and a longer time before additional treatment is needed.
[BACKGROUND AND OBJECTIVE] The optimal treatment for patients with prostate cancer with primary lymph node metastases (LNMs) is still a matter of debate.
- 95% CI 1.07-1.56
APA
Korn P, Lischewski F, et al. (2025). Radical Prostatectomy Combined with Prostate Specific Membrane Antigen-radioguided Lymph Node Dissection is Associated with Longer Treatment-free Survival for Patients with Primary Lymph Node-positive Prostate Cancer.. European urology open science, 82, 201-207. https://doi.org/10.1016/j.euros.2025.10.018
MLA
Korn P, et al.. "Radical Prostatectomy Combined with Prostate Specific Membrane Antigen-radioguided Lymph Node Dissection is Associated with Longer Treatment-free Survival for Patients with Primary Lymph Node-positive Prostate Cancer.." European urology open science, vol. 82, 2025, pp. 201-207.
PMID
41322961 ↗
Abstract 한글 요약
[BACKGROUND AND OBJECTIVE] The optimal treatment for patients with prostate cancer with primary lymph node metastases (LNMs) is still a matter of debate. Radical prostatectomy (RP) combined with prostate-specific membrane antigen (PSMA)-radioguided surgery (RGS) may be a helpful technique in removal of LNMs detected on preoperative PSMA positron emission tomography (PET) in comparison to conventional lymph node dissection (LND). The aim of our retrospective analysis was to determine whether addition of PSMA-RGS at primary radical prostatectomy (RP) is associated with longer survival.
[METHODS] Technetium-PSMA-I&S was administered preoperatively to facilitate LND during RP in the RGS group. Standard descriptive statistics were used to outline differences in patient characteristics. To address imbalance of covariates, we created matched samples using exact matching before assessing survival outcomes using Cox regression analyses.
[KEY FINDINGS AND LIMITATIONS] Matched samples were created for a cohort comprising 46 patients who underwent RP with RGS, and 42 patients who underwent RP without RGS, with matching according to LNM distribution, number of LNMs on preoperative PSMA PET scans, and surgical margin status. Multivariate Cox regression revealed an association between longer treatment-free survival (TFS) and PSMA RGS (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.30-0.94). A higher number of positive lymph nodes (HR 1.29, 95% CI 1.07-1.56) and positive surgical margins (HR 1.86, 95% CI 1.06-3.25) were associated with shorter TFS. The main limitations are the retrospective design and small sample size.
[CONCLUSIONS AND CLINICAL IMPLICATIONS] Addition of PSMA-RGS at primary RP was associated with longer TFS for patients with limited PSMA PET-positive locoregional LNMs.
[PATIENT SUMMARY] We looked at whether a technique to label and detect lymph node metastases during prostate cancer surgery is linked to better cancer control for patients whose preoperative scans showed limited spread to the lymph nodes. We found that this approach may lead to better cancer control after surgery and a longer time before additional treatment is needed.
[METHODS] Technetium-PSMA-I&S was administered preoperatively to facilitate LND during RP in the RGS group. Standard descriptive statistics were used to outline differences in patient characteristics. To address imbalance of covariates, we created matched samples using exact matching before assessing survival outcomes using Cox regression analyses.
[KEY FINDINGS AND LIMITATIONS] Matched samples were created for a cohort comprising 46 patients who underwent RP with RGS, and 42 patients who underwent RP without RGS, with matching according to LNM distribution, number of LNMs on preoperative PSMA PET scans, and surgical margin status. Multivariate Cox regression revealed an association between longer treatment-free survival (TFS) and PSMA RGS (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.30-0.94). A higher number of positive lymph nodes (HR 1.29, 95% CI 1.07-1.56) and positive surgical margins (HR 1.86, 95% CI 1.06-3.25) were associated with shorter TFS. The main limitations are the retrospective design and small sample size.
[CONCLUSIONS AND CLINICAL IMPLICATIONS] Addition of PSMA-RGS at primary RP was associated with longer TFS for patients with limited PSMA PET-positive locoregional LNMs.
[PATIENT SUMMARY] We looked at whether a technique to label and detect lymph node metastases during prostate cancer surgery is linked to better cancer control for patients whose preoperative scans showed limited spread to the lymph nodes. We found that this approach may lead to better cancer control after surgery and a longer time before additional treatment is needed.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.
- Health-related Quality of Life With ARPIs in mHSPC: Insights From a Network Meta-analysis.
- Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases.
- Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.
- High-Risk Prostate Cancer Treated with Radiation Therapy: Favorable Outcomes in Men with PSA > 20 as the Sole High-Risk Factor.
- Real-world precision medicine data in metastatic prostate cancer - a retrospective cohort study.